Skip to main content

Pharma News

 

Clinical courses

 

Clinical research courses

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • CANOPY-1 Phase III study did not demonstrate the statistically significant primary endpoints

    Novartis announced that the CANOPY-1 Phase III study did not demonstrate the statistically significant primary endpoints of overall survival (OS) and progression-free survival (PFS) in patients treated with canakinumab (ACZ885) combined with pembrolizumab plus platinum-based doublet chemotherapy, compared to patients receiving placebo in combination with pembrolizumab plus platinum-based doublet chemotherapy.

  • PCI elected Young executive member in its panel

    President of Gujarat Pharmacy Council Dr. Montukumar Patel has won the election of executive member in pharmacy council of India (PCI). Dr. Montukumar Patel was elected unopposed as executive member. He was also became youngest president of Gujarat State Pharmacy Council few years back.

    Years later, Gujarati youth got a place in Delhi Pharmacy Council of India. Dr. Montukumar was elected as the youngest executive member in the history of India.With 76 thousand registered pharmacists in Gujarat and 12 lakh pharmacists across India will get benefit from young panel.

  • Advanced Radiation Therapy, LLC and Apollo Healthcare Announce Strategic Partnership

    Advanced Radiation Therapy, LLC (ART) and Apollo Healthcare have today announced a strategic partnership aimed at easing the challenge radiation oncology clinics have in pre-authorizing patients for insurance coverage for innovative radiation cancer therapies.

  • FDA approves Susvimo for macular degeneration

    Roche announced that the U.S. Food and Drug Administration (FDA) has approved Susvimo  (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people with neovascular or wet age-related macular degeneration (nAMD) who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections. Neovascular AMD is a potentially blinding condition that requires treatment with eye injections as often as once a month.

  • Aino Health is approved by Swedish Social Insurance Agency as a workplace-oriented rehabilitation support organizer

    Swedish Social Insurance Agency (Försäkringskassan), has granted Aino Health approval to provide proactive and rehabilitative efforts in the workplace. In collaboration with Swedish Social Insurance Agency, Aino Health can offer support investigating, planning, implementing and following up on work-oriented measures.  

    The purpose of the grant is to prevent sick leave and make it easier for employees to return to work after sick leave. 

  • Dupixent (dupilumab) is the first biologic to significantly reduce itch and skin lesions in Phase 3 trial for prurigo nodularis, demonstrating the role of type 2 inflammation in this disease

    PARIS and TARRYTOWN, N.Y. – October 22, 2021 - A pivotal Phase 3 trial evaluating Dupixent® (dupilumab) in adults with uncontrolled prurigo nodularis, a chronic type 2 inflammatory skin disease that causes extreme itch and skin lesions, met its primary and all key secondary endpoints, showing that Dupixent significantly reduced itch and skin lesions compared to placebo in this investigational setting. The impact of uncontrolled prurigo nodularis on quality of life is one of the highest among inflammatory skin diseases with intense, chronic itch.

  • Experts Discuss Gender and Stigma Barriers to TB Care at Union Conference

    Global Coalition Against Tuberculosis (GCAT) and Karnataka Health Promotion Trust (KHPT) jointly organized the session The policymaker’s roundtable: Addressing gender and stigma barriers to TB Care on 21st October 2021 at the 52nd Union Conference held virtually. The panel members discussed the role of gender and stigma affecting access to TB services and care and the need for a TB-Mukt Bharat.

  • Two vaccine doses boost antibody levels in the airways after COVID-19

    Antibodies in the airways quickly wane after SARS-CoV-2 infection, but vaccination results in a strong increase in antibody levels, especially after two doses, according to a new study from Karolinska Institutet in Sweden published in the journal JCI Insight. The results suggest that having a second dose of vaccine also after recovering from COVID-19 may be important for protecting against re-infection and to prevent transmission.

  • LumiraDx receives approval for its COVID-19 Antigen Test for use in India

    LumiraDx a next-generation point of care diagnostics testing company announced it has received emergency use approval by India’s Central Drugs Standard Control Organisation for its SARS-CoV-2 Antigen test for use in India. The test detects antigen nucleocapsid protein from a nasal swab with results in under 12 minutes from sample application.

  • Amgen Successfully Completes Acquisition Of Teneobio, Inc

    Amgen announced that it has successfully completed its previously announced acquisition of Teneobio, Inc. (Teneobio). Effective as of Oct. 19, 2021, Amgen has acquired all outstanding equity of Teneobio in exchange for a USD 900 million upfront cash payment, as well as future contingent milestone payments, to former Teneobio equity holders potentially worth up to an additional USD 1.6 billion in cash.

Subscribe to Pharma News